Monashee Investment Management LLC Trims Position in Structure Therapeutics Inc. (NASDAQ:GPCR)

Monashee Investment Management LLC cut its holdings in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 17.3% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 132,000 shares of the company's stock after selling 27,608 shares during the period. Structure Therapeutics makes up approximately 0.5% of Monashee Investment Management LLC's investment portfolio, making the stock its 19th largest position. Monashee Investment Management LLC owned about 0.23% of Structure Therapeutics worth $3,580,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the business. ANTIPODES PARTNERS Ltd increased its holdings in Structure Therapeutics by 115.0% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock worth $28,000 after purchasing an additional 553 shares in the last quarter. GAMMA Investing LLC lifted its stake in Structure Therapeutics by 4,155.6% in the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company's stock valued at $31,000 after buying an additional 1,122 shares during the period. FNY Investment Advisers LLC bought a new position in Structure Therapeutics during the fourth quarter worth $40,000. Virtus ETF Advisers LLC grew its stake in shares of Structure Therapeutics by 25.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock valued at $61,000 after buying an additional 455 shares during the period. Finally, Assetmark Inc. increased its holdings in shares of Structure Therapeutics by 72.3% during the fourth quarter. Assetmark Inc. now owns 2,271 shares of the company's stock valued at $62,000 after acquiring an additional 953 shares in the last quarter. 91.78% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have issued reports on GPCR shares. Stifel Nicolaus initiated coverage on Structure Therapeutics in a research note on Wednesday, January 8th. They set a "buy" rating and a $50.00 price target for the company. William Blair assumed coverage on Structure Therapeutics in a report on Friday, February 28th. They set an "outperform" rating for the company. Citigroup assumed coverage on Structure Therapeutics in a research note on Friday. They set a "buy" rating and a $60.00 price objective on the stock. Finally, HC Wainwright reiterated a "buy" rating and issued a $80.00 target price on shares of Structure Therapeutics in a research note on Tuesday, April 22nd. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $78.63.

Structure Therapeutics Price Performance

Structure Therapeutics stock traded down $0.04 during mid-day trading on Monday, reaching $27.05. 318,401 shares of the stock traded hands, compared to its average volume of 920,609. Structure Therapeutics Inc. has a 12-month low of $13.22 and a 12-month high of $62.74. The business's 50-day moving average is $20.52 and its 200-day moving average is $27.30. The stock has a market capitalization of $1.55 billion, a PE ratio of -36.50 and a beta of -1.35.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.01. Equities analysts anticipate that Structure Therapeutics Inc. will post -0.82 EPS for the current fiscal year.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.